TAF1D and gastric cancer: We observed that the mRNA expression level of TAF1D was considerably elevated in 19 cancers by analyzing the TCGA Pan-Cancer dataset (Fig. 1A), similarly, we also investigated the protein expression levels of TAF1D in various malignant tumors, which showed that breast, ovarian, cervical, skin, pancreatic, urothelial, lung, and stomach cancers displayed strong or moderate cytoplasmic and membranous positivity, indicating a high protein expression level of TAF1D in these cancers (Fig. S1).